Retinal Vein Occlusion Epidemiology Report 2021 – Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Vein Occlusion – Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This ‘Retinal Vein Occlusion (RVO) – Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical and forecasted RVO epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Retinal Vein Occlusion Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of RVO, Diagnosed Prevalent Cases of RVO, Gender-specific Diagnosed Prevalent Cases of RVO, Age-specific Diagnosed Prevalent Cases of RVO, Type-specific Diagnosed Prevalent Cases of RVO, and Treated Cases of RVO in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.
RVO Detailed Epidemiology Segmentation
- In the year 2020, the total prevalent cases of RVO were 2,308,457 cases in the 7MM, which is expected to increase in the forecast period (2021-2030).
- The United States, in 2020, accounted for 1,160,900 cases prevalent cases of RVO, which is expected to rise in the year 2030. In EU-5 countries the highest number of prevalent Cases of RVO was in Germany, i.e., 217,282, in the year 2020. The lowest number of cases observed in Spain during the study period.
- In 2020, the total diagnosed prevalent cases of RVO in the 7MM were 2,020,233.
- In the 7MM, the total gender-specific prevalent cases of RVO were 951,432 in males and 1,068,801 in females in the year 2020
- In the 7MM, the total diagnosed cases of RVO by age distribution were 1,166,736, 535,472, and 318,025 cases for the age group less than 65 years, 65-74 years, and ?75 years, in 2020.
- In the 7MM, CRVO contributed to 407,058 cases in 2020. Furthermore, in 2020, there were around 1,613,175 BRVO cases.
Report Highlights
- 10-Year Forecast of RVO
- 7MM Coverage of RVO
- Prevalent Cases of RVO in the 7MM
- Diagnosed Prevalent Cases of RVO in the 7MM
- Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Age-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Type-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Treated Cases of RVO in the 7MM
Key Questions Answered
- What are the disease risk, burdens, and unmet needs of RVO?
- What is the historical RVO patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of RVO at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to RVO?
- Out of the countries mentioned above, which country would have the highest prevalent population of RVO during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Key Topics Covered:
1. Key Insights
2. Executive Summary of Retinal Vein Occlusion (RVO)
3. RVO: Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Risk Factors and Causes
3.4. Pathophysiology
3.5. Diagnosis
3.5.1. Optical coherence tomography
3.5.2. Fluorescein angiography
3.5.3. Systemic Evaluation
3.5.4. Optical coherence tomography angiography (OCTA)
3.5.5. Fundus Autofluorescence
3.5.6. Laboratory Test
3.5.7. European Society of Retina Specialists Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Epidemiology Key Findings
4.2. Assumptions and Rationale
4.3. Epidemiology Scenario: 7MM
4.3.1. Total Prevalent Cases of RVO in the 7MM
4.3.2. Total Diagnosed Prevalent cases of RVO in the 7MM
4.3.3. Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM
4.3.4. Age-specific Diagnosed Prevalent Cases of RVO in the 7MM
4.3.5. Type-specific Diagnosed Prevalent Cases of RVO in the 7MM
4.3.6. Treated cases of RVO in the 7MM
4.4. The United States Epidemiology
4.4.1. Total Prevalent Cases of RVO in the United States
4.4.2. Total Diagnosed Prevalent cases of RVO in the United States
4.4.3. Gender-specific Diagnosed Prevalent Cases of RVO in the United States
4.4.4. Age-specific Diagnosed Prevalent Cases of RVO in the United States
4.4.5. Type-specific Diagnosed Prevalent Cases of RVO in the United States
4.4.6. Treated cases of RVO in the United States
4.5. EU-5 Epidemiology
4.6. Germany
4.7. France
4.8. Italy
4.9. Spain
4.10. The United Kingdom
4.11. Japan Epidemiology
5. Recognized Establishments
6. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/399pn4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
